Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. (Q53065761)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Wan-Teck Lim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

S S Leong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

M K Ang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

C K Toh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

F Gao

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

B Chowbay

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

E H Tan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

17 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

718-722

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic varie

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ425

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ425

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20716628%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference